Mucus barrier correction as a target in complex treatment of gastroesophageal reflux disease
The aim of our study was to evaluate the clinical efficacy of esophageal mucus barrier correction by complex treatment with sodium hyaluronate and sodium alginate (Hyalera/ Gastropiù Bustine) application in patients with gastroesophagic reflux disease (GERD). We conducted a multicenter, randomized, open, comparative study with parallel monitoring to evaluate the effectiveness and safety of combination therapy for patients with GERD using the sodium hyaluronate and sodium alginate (Hyalera/Gastropiù Bustine). Under our supervision, there were 72 patients with GERD aged 18 to 65years. Women were 30 (41.7%), men 42 (58.3%). The criterion for inclusion in the study was the presence of GERD symptoms (primarily heartburn) with endoscopic and morphological confirmation. Omeprazole at a dose of 20mg 2 times a day and domperidone at a dose of 10mg 3 times a day were used as basic therapy in both groups. In the first group, an additional sodium hyaluronate and sodium alginate (Hyalera/Gastropiù Bustine) emulsion of 15ml sticks (Alpiflor, Italy) was prescribed. The emulsion was administered 1 stick after a meal 3 times a day.
